Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research

Published on March 31, 2017 in New-York, New-York (USA)

Back to all press releases

New York, N.Y. – March 29, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that data on its gene-edited allogeneic CAR T-cells will be presented at the American Association for Cancer Research (AACR) Annual Meeting. This includes both wholly-controlled Cellectis programs and Pfizer/Cellectis collaboration programs. The meeting will be held from April 1st to April 5th, 2017 in Washington, D.C., USA.

Cellectis presentation:

• UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting CD22 with CAR T-cells 

Agnès Gouble1, Cécile Schiffer-Mannioui1, Séverine Thomas1, Anne-Sophie Gautron1, Laurent Poirot1, Julianne Smith2.

1Cellectis, Paris, France; 2Cellectis, New York, NY

Innate Effectors in Immunity to Cancer session – section 30

April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

Pfizer/Cellectis presentations:

• Allogeneic EGFRvIII Chimeric Antigen Receptor T Cells for Treatment of Glioblastoma

Oi Kwan Wong1, Mathilde Dusseaux2, Jing-Tyan Ma1, Melinda Au1, Sophie Leduc2, Joyce Chou1, Jessica M. Yu1, Marjorie Bateman1, Thomas Pertel1, Kevin C. Lindquist1, Julianne Smith3, Barbra Sasu1, Shu-Hui Liu1.

1Pfizer Inc., South San Francisco, CA; 2Cellectis, Paris, France; 3Cellectis, New York, USA

Innate Effectors in Immunity to Cancer session – section 30

April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

• Differential modulation of the PD-1 pathway impacts the anti-tumor activity of CAR T cells

Regina J. Lin1, Anne-Sophie Gautron2, Laurent Poirot2, Oi Kwan Wong1, Barbra Sasu1, Bijan Boldajipour1.

1Pfizer, South San Francisco, CA; 2Cellectis, Paris, France; 3Cellectis, New York, USA

Late-Breaking Research: Immunology session – section 35

April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

Collaboration with Pfizer

In June 2014, Cellectis and Pfizer began collaborating on a joint clinical development program for UCAR-T therapies, in the field of oncology, directed at numerous targets selected by Pfizer and several targets selected by Cellectis.

Download the PDF file